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Abstract
Background: The recurrence of cardiac events in patients with idiopathic ventricular fibrillation
(VF) excluding patients with the Brugada syndrome is unclear since this entity remains present in
previous studies.
Methods: Since 1992, 18 patients (72% male) with idiopathic VF out of 455 ICD implants were
treated with an implantable cardioverter defibrillator (ICD). The mean age at first ICD implantation
was 42 ± 14 years. Brugada syndrome, as well as other primary electrical diseases (e.g. long QT),
were systematically excluded in all patients by the absence of the typical electrocardiogram (ST
elevation in the right precordial leads) at rest and/or after pharmacological tests (ajmaline,
flecainide, or procainamide). Recurrence of cardiac events was prospectively assessed.
Results: During a mean follow-up period of 41 ± 27 months, VF recurrence with appropriate
shock occurred in 7 patients (39%) covering a total of 27 shocks. The median time to first
appropriate shock was 12 ± 9 months. There were no deaths. In the electrophysiological study,
39% of patients were inducible, but inducibility failed to predict subsequent arrhythmic events.
Forty-four percent of patients suffered 21 inappropriate shocks, which were caused by sinus
tachycardia, atrial arrhythmias or lead malfunction.
Conclusion: Idiopathic ventricular fibrillation patients have a high recurrence rate of potentially
fatal ventricular arrhythmias, excluding patients with the Brugada syndrome or other known causes.
ICD prevents sudden cardiac death but inappropriate shocks remained a major issue in this young
and active population.
Background
Idiopathic ventricular fibrillation (VF) is defined as spon-
taneous ventricular fibrillation in the absence of any struc-
tural heart disease, including coronary artery disease,
valvular heart disease, myocarditis, cardiomyopathy or
electrophysiological diseases, with a well-defined cause,
such as the long QT syndrome, the Brugada syndrome,
ventricular pre-excitation (WPW), and drug intoxication
[1]. The consensus statement of the joint steering commit-
tees of the UCARE registry of Europe and of the idiopathic
VF registry of US reported in 1997 that patients with the
Brugada syndrome should be considered a variant of idi-
opathic VF [1].
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Brugada syndrome is characterized by a unique electrocar-
diographic (ECG) pattern of right bundle branch block
with ST elevation in the right precordial leads. Transient
forms of the disease in which the ECG normalizes for a
period of time have been described. Administration of
sodium channel blockers will unmask the abnormal ECG
in patients with transient normalized ECGs [2,3]. The
American Heart Association has recently proposed diag-
nostic criteria for the Brugada syndrome [4]. Moreover,
the incidence of Brugada syndrome among patients with
idiopathic VF remains unclear. The prevalence of a Bru-
gada type ECG pattern was reported in 21% [5] and 24%
[6] of idiopathic VF populations. However, on the basis of
pharmacological tests, it has been speculated that up to
40% – 60% of patients diagnosed with idiopathic VF
might actually suffer from the Brugada syndrome [7].
Since this is a new clinical entity, older publications prob-
ably classified some patients with Brugada syndrome as
idiopathic VF, since intravenous administration of a
sodium channel blocker to unmask a concealed form of
the disease was not systematically performed. Our report
describes the clinical and electrophysiological characteris-
tics of consecutive sudden cardiac arrest survivors from
idiopathic VF who received an ICD, and in whom electri-
cal and structural heart diseases including Brugada syn-
drome, long QT, arrhythmogenic right ventricular
dysplasia, and hypertrophic cardiomyopathy character-
ized by a high recurrence rate, were systematically
excluded.
Methods
Patient population
The total population under investigation included 455
consecutive patients who received a third generation ICD,
with stored electrograms capabilities for hemodynami-
cally poorly tolerated ventricular tachyarrhythmias, from
1992 to 2000. Of these, 29 were initially diagnosed as idi-
opathic VF associated with a structurally normal heart,
normal left and right ventricular ejection fraction and nor-
mal coronary arteries. During the follow-up, 11 patients
developed a new diagnosis potentially explaining VF, and
were excluded from the final analysis. Four had right ven-
tricular dysplasia, 5 had Brugada syndrome with the typi-
cal ECG manifestations after a drug challenge, and 2
patients had long QT syndrome. A final diagnosis of idio-
pathic VF was made in the remaining 18 patients. All
patients had survived either an episode of cardiac arrest
due to VF (12 patients) or a syncopal episode associated
with documented self-terminating polymorphic ventricu-
lar tachycardia or fibrillation (6 patients). In 15 patients,
the documented VF was seen during daily activity (one
episode during sustained effort) and in 3 patients, during
night-time. Out of the 18 patients, 10 had a previous his-
tory of unexplained syncope.
Definitions and investigation
Idiopathic VF was defined as VF in the absence of demon-
strable cardiac abnormalities as previously reported [1].
Thus, we excluded other known causes of VT/VF such as
WPW syndrome, congenital long QT syndrome, short-
coupled torsade de pointes, catecholamine-induced poly-
morphic VT, and Brugada syndrome. No patient had a
past history of ischemic heart disease, congestive heart
failure or family history of unexpected sudden cardiac
death. All patients had a normal physical examination,
blood testing and exercise test. Structural heart disease
was excluded in all by echocardiography, cardiac catheter-
ization including right and left ventricular angiography
and coronary angiography. Patients on anti-arhythmic
therapy before their cardiac arrest were excluded from the
study, as well as those with electrolyte disturbances, his-
tory of significant alcohol or drug abuse or prolonged
QTc. Of the 18 patients, 10 patients had normal right ven-
tricular endomyocardial biopsy and 8 patients had a nor-
mal cardiac magnetic resonance imaging. Moreover, in 5
patients, an ergonovine provocation test was performed
to exclude coronary artery spasm. Brugada syndrome was
systematically excluded in all patients by negative serial
ECG recordings with the typical coved or saddle shaped-
type ST-segment elevation in the right precordial leads. All
patients received iv administration of a sodium channel
blocker to unmask a concealed form of the disease and all
tests were negative. Flecainide (2 mg/kg body weight) was
used in 9 patients, procainamide (10 mg/kg body weight)
in 4 patients, and ajmaline (0.7 mg/kg body weight) in 7
patients.
Electrophysiological study
Programmed electrical stimulation was performed in all
patients using up to 3 extra-stimuli at 3 different drive
cycle lengths (600, 500, and 430 ms) delivered to the right
ventricular apex. The coupling interval of the first 2 extra-
stimuli was not shorter than 180 ms and not shorter than
200 ms for the third extra-stimuli. In case of non-induci-
bility, programmed stimulation was also performed from
the right ventricular outflow tract. Sustained VF was
defined as VF at a cycle length ≤ 200 ms and lasting ≥ 30
seconds or requiring immediate defibrillation. Sustained
ventricular tachycardia (VT) was defined as VT lasting ≥ 30
seconds or requiring termination secondary to hemody-
namic instability. Non-sustained VT was defined as >6
consecutive ventricular complexes or VT lasting <30
seconds.
ICD implantation
All patients received a transvenous ICD with stored elec-
trograms. Recorded episodes were reviewed and adjudi-
cated as appropriate or inappropriate therapies. VF was
defined at follow-up as consecutive ventricular beats
recorded from the device at a cycle length of 240 msec orBMC Medicine 2005, 3:1 http://www.biomedcentral.com/1741-7015/3/1
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less. In all patients, the ICD was programmed with only 1
ventricular fibrillation detection zone at 180 bpm (333
msec). Only shock therapy was programmed. All patients
were seen at follow-up in our centre.
Statistical analysis
All data are expressed as mean ± standard deviation. Kap-
lan-Meier analysis was used to analyze time intervals until
the first appropriate shock.
Results
The study cohort consisted of 13 men and 5 women
(Table 1), with a mean age at the first ICD implantation
of 42 ± 14 years (range 20 to 70 years). Baseline electro-
cardiograms were normal in 16 patients. One patient had
a left bundle branch block and 1 had a right bundle
branch block. The mean QTc for the entire population was
410 ± 20 msec. All patients had a normal left ventricular
ejection fraction (≥ 50%) without regional wall motion
abnormalities. Mean left ventricular ejection fraction (EF)
was 69 ± 8% (range 52 to 81%). No patient had signifi-
cant coronary artery disease (defined as ≥ 50% stenosis).
Microscopic examination of right ventricular biopsy spec-
imens in 10 patients showed no evidence of a viral, infil-
trative or dysplasic process in the myocardium. Baseline
electrophysiological studies were performed in all
patients and showed normal sinus node, atrioventricular
node and His-Purkinje function in all. Inducible sus-
tained ventricular arrhythmias occurred in 7 patients
(39%). From these, 4 patients had sustained VF and 3
patients had sustained inducible monomorphic VT or
ventricular flutter (cycle length 230 ± 20 ms). Two extra-
stimuli were required in 5 patients and 3 extra-stimuli in
2 patients. Non-sustained VT-VF was induced in 3
patients. No arrhythmia could be induced in 8 patients.
Long-term outcome
After a mean follow-up of 41 ± 27 months (ranging from
5 to 92 months), 7 of the 18 patients (39%) with idio-
pathic VF had VF or sustained polymorphic VT recurrence
and received appropriate shocks (Table 1). These patients
experienced a total of 27 shocks; 5 of them had more than
1 episode (2 to 7). Mean time to first appropriate shock
was 12 ± 9 months (ranging from 0.4 to 27 months). No
arrhythmic storm was observed at follow-up (defined as ≥
3 separate VT/VF episodes within 24 h). With the use of
Table 1: Clinical characteristics and outcome of 18 patients with idiopathic VF
Baseline Characteristics ICD Therapy
Patient Age 
(years) 
sex
CE Drug test to 
exclude 
Brugada
PES AS NSVT IS Ind S Time to 
1st AS 
(months)
Follow-
up 
(months)
AAD 
during 
follow-up
1 47,M Sy-VF F SMVT 6 7 - - 4 17 sotalol
2 51,F CA F NI 7 21 - - 1 19 sotalol
3 6 6 , M C A A J V F ---- - 5 -
4 70,F CA P NI - - 6(af) - - 19 amiodaron
e
5 46,M CA F NI - 1 1(af) - - 23 sotalol
6 20,M Sy-VF A VF - - 3(st-lp) - - 92 b-blocker
7 46,F CA P VF - 120 - - - 27 sotalol
8 4 0 , M C A A N S V T1--- 1 3 7 5 -
9 33,M Sy-VF F NSVT - 1 - - - 19 -
10 26,M CA F NI 1 - 3(st-lp) - 7 9 sotalol
1 1 3 3 , F C A FN I ---- - 1 8 -
12 50,F CA F SMVT 6 - 1(st) - 13 86 flecainide
13 25,M CA AJ + P NSVT - 1 - - - 62 -
14 36,M CA AJ NI 2 - 2(af) 4 27 55 sotalol
15 58,M Sy-VF AJ NI - - 3(af) 2 - 57 sotalol
1 6 4 4 , M C A F  +  P N I ---- - 4 8 -
17 28,M Sy-VF F VF 4 - 2(st) - 18 55 sotalol
1 8 3 5 , M S y - V F A S M V T ---- - 5 9 -
CE: clinical events; CA: cardiac arrest; Sy-VF: syncope with documented self-terminating polymorphic VT or VF
PES: programmed electrical stimulation; M: male; F: female
SM: sustained monomorphic; VT: ventricular tachycardia; VF: ventricular fibrillation
NS: non sustained; NI: non inducibility; af: atrial fibrillation; st: sinus tachycardia; lp: lead problem
AS: appropriate shock; IS: inappropriate shock; Ind S: indeterminate cause for shocks;
AAD: antiarrhythmic drug; F: flécaïnide; AJ: ajmaline; P: procainamideBMC Medicine 2005, 3:1 http://www.biomedcentral.com/1741-7015/3/1
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stored electrograms, 6 patients had documented non-sus-
tained polymorphic VT or VF for a total of 149 episodes
(range 1 to 120). Four of them have not received any
appropriate shock. These episodes were detected by the
ICD but shock delivery was appropriately aborted by the
non-committed function of the device. There was no rela-
tionship between the initial clinical and arrhythmic pres-
entation and subsequent arrhythmic events recorded from
the ICD at follow-up (Table 1). From the intracardiac elec-
trograms, the arrhythmia initiation was always associated
with PVCs with a mean coupling interval of 300 ± 35 ms.
A long-short initiating sequence of VF was never observed.
In 5 patients, multiple VF episodes were recorded by the
ICD, all of which for a single patient were associated with
the same PVC coupling interval. Since the stored electro-
grams in the present study were obtained from endocar-
dial sites and were single-channel recordings, we could
not assess the origin of the PVCs. The mean QTc at the
time of VF recurrence was normal in all patients (mean
418 ± 22 msec). The ICD effectively recognized and
promptly treated all the polymorphic VT or VF recurrences
and prevented the possible occurrence of sudden cardiac
death. No death was reported during follow-up. Non-
invasive follow-up examinations failed to detect any new
structural heart disease or primary electrical disease such
as long QT or Brugada syndrome.
Value of electrophysiological Testing
Programmed electrical stimulation failed to predict subse-
quent cardiac events. The sensitivity and specificity were
43 and 64%, respectively. The positive and negative pre-
dictive values were also 43 and 64%, respectively, that is
not considered clinically useful.
Causes and incidence of inappropriate shocks
In this population, we observed a high incidence of inap-
propriate shocks. Eight of the 18 patients (44%) received
an inappropriate shock for a total of 21 discharges. Atrial
fibrillation was responsible for 57% of them (12 episodes
in 4 patients). These were older patients with a mean age
of 53 ± 14 years. Six inappropriate shocks (4 patients)
were triggered by sinus tachycardia. These patients were
younger with a mean age of 31 ± 13 years. Lead malfunc-
tion caused 3 inappropriate shocks in 2 patients. Six
shocks in 2 patients were classified as of unknown cause,
even after careful examination of the intracardiac electro-
grams. These shocks were probably inappropriate since no
clinical symptoms occurred during these episodes and
these 2 patients already experienced inappropriate shocks
for atrial fibrillation.
Device follow-up
During the follow-up period, first-time generator replace-
ment was performed in 9 patients after a mean of 43 ± 11
months after initial implantation (range 21 to 58). End of
life battery was the indication for replacement in 8
patients, and 1 had an ICD component failure. A second
replacement was done in 2 patients. Lead replacement
was also indicated in 2 patients for lead insulation frac-
ture. Adjunctive anti-arrhythmic drugs were required in
11 patients after ICD implantation in order to control for
the occurrence of appropriate or inappropriate shocks
(Table 1).
Discussion
To our knowledge, this report is the first study to describe
the clinical outcome of ICD patients with a diagnosis of
idiopathic VF in whom the Brugada syndrome, character-
ized by a high recurrence rate, was systematically
excluded. Since there is a wide variability in the ECG
expression in individual patients with the Brugada syn-
drome, we performed iv administration of sodium chan-
nel blockers to unmask the ECG features of the syndrome
in all our idiopathic VF patients. Two studies reported the
long-term outcome of patients with idiopathic VF without
the Brugada syndrome [5,6]. Viskin et al. [5] performed iv
administration of a sodium channel blocker to unmask a
concealed form of Brugada syndrome in only 15 % of
their idiopathic VF population, whereas Remme et al. [6]
tested the effect of an iv sodium channel blocker on ECG
morphology in only 30% of the patients. The unique find-
ing of the present report is the high recurrence rate of sus-
tained ventricular arrhythmias in this well-characterized
idiopathic VF group, even after a careful systematic evalu-
ation to exclude the presence of Brugada syndrome. After
a mean follow-up of 41 ± 27 months, 39% of the patients
received an appropriate ICD discharge for VF or polymor-
phic VT. In accordance with references [8,9], ICD therapy
offered good protection against fatal outcome due to
recurrent ventricular arrhythmias, with no mortality dur-
ing the follow-up. The high recurrence rate is consistent
with the relatively high recurrence rate of arrhythmic
events or sudden death from the UCARE registry [10], as
well as the high frequency of electrical discharges from
ICDs reported in a large series of patients with idiopathic
VF [6,8,9]. In comparison, appropriate ICD discharges
have been reported in 48% of arrhythmogenic right ven-
tricular dysplasia population [11], 40 to 56% of inducible
population receiving an ICD [12,13] and 23% (7%/year)
in the hypertrophic cardiomyopathy population [14].
However, some authors have reported a more benign clin-
ical course of their idiopathic VF population with a lower
recurrence rate [15-17]. Our high ICD discharge rate
might also be explained by the rapid ICD intervention for
fast ventricular arrhythmia that could have been self-ter-
minated. The definition of idiopathic VF remains
problematic, since numerous studies including idiopathic
VF population are heterogeneous. Indeed, 61% (11/18
patients) of our cohort remained free of sustained
arrhythmia recurrence during follow-up despite the sameBMC Medicine 2005, 3:1 http://www.biomedcentral.com/1741-7015/3/1
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initial VF or syncopal presentation. Of note, idiopathic VF
is always a diagnosis of exclusion. The patients in our
cohort, as well as in other reported series, had normal
hearts, as defined by clinical, non-invasive and invasive
testing. Even after a careful investigation, a transient phe-
nomenon such as a reversible localized myocardial dis-
ease, silent myocardial ischemia due to coronary artery
spasm or sudden manifestation of an unknown primary
electrophysiological disease could easily be missed by the
clinician, and be responsible for the VF episode. Idio-
pathic VF is in fact an amalgam of different diseases in
which the first clinical manifestation is VF. The ultimate
answer probably lies in a more comprehensive approach
and a more precise understanding of the molecular genet-
ics and associated electrophysiological abnormalities in
finding a specific treatment avoiding ICD implantation
with its associated complications.
Anti-arrhythmic drugs have also been used in this clinical
condition. Belhassen et al. [18] reported excellent results
in their idiopathic VF population with EP-guided therapy
using Class 1A drugs, primarily quinidine; no death
occurred during a mean follow-up of >9 years. Recent evi-
dence also suggests that frequent premature ventricular
contractions arising from the Purkinje system are respon-
sible for initiation of ventricular fibrillation, and can be
mapped and ablated in selected patients [19]. Until
another proven therapy has been assessed prospectively,
the possibility of VF recurrence mandates ICD implanta-
tion as currently proposed in ICD guidelines [20].
Electrophysiological findings
The inducibility rate (39%) of sustained VT/VF observed
in our study is also in accordance with the results of the
UCARE registry [10]. Of importance, programmed electri-
cal stimulation was of limited value with a poor sensitivity
and specificity. Moreover, inducibility failed to predict
subsequent arrhythmic events. Our findings differ from
the observed 79% average inducibility rate reported by
Belhassen et al. [17,18]. This may be due to different
patient characteristics and stimulation protocol. Our
study excluded patients with Brugada syndrome known to
have a high inducibility rate [21]. Compared to our stim-
ulation protocol, Belhassen et al. [22] used up to 3 extra-
stimuli, 2 basic cycle lengths, 2 RV sites (first RVA, then
RVOT), and repetition of extra-stimulation (n = 10 for
double, and n = 5 for triple) at the shortest coupling inter-
vals that resulted in ventricular capture. Three patients
had a fast monomorphic VT inducible even if the clinical
presentation was aborted sudden cardiac death. This may
suggest an underlying structural heart disease undetected
by the current investigation. Although general cardiac
function can be normal, patients might have discrete
abnormalities, which are currently unidentifiable. Better
risk stratification is required to identify patients who will
experience recurrent VF over time. Therefore, defibrillator
implantation could be seen as the primary therapy in
patients with idiopathic VF, since no stratification has yet
identified patients at risk of arrhythmia recurrence.
ICD limitations
The impact of multiple battery replacements over time in
this young population with idiopathic VF needs to be
emphasized. It is noteworthy that half the population (9/
18 patients) had an ICD replacement and 2 other patients
had their transvenous lead replaced during follow-up. We
also observed a high incidence of inappropriate shocks
(44%), mainly caused by atrial fibrillation and sinus tach-
ycardia. This is well in accordance with other studies
where up to 40% inappropriate discharge rates were
observed even with fourth generation ICDs [23]. The
addition of an anti-arrhythmic drug to decrease the inci-
dence of inappropriate shocks was required in this group.
Four patients experienced atrial fibrillation, which might
indicate the presence of an associated primary electro-
physiological disease also affecting the atrium. In patients
with idiopathic VF, the characteristics, is the recurrence of
VF and not monomorphic VT compared to other ventricu-
lar arrhythmias. To decrease the number of inappropriate
shocks, one should program a higher VF zone around
200–220 bpm and a lower monitoring zone to detect
atrial arrhythmia. Third-generation ICD still have limita-
tions and complications over time, with a significant pro-
portion of patients having hardware-related
complications or inappropriate shocks [24]. Future devel-
opments in ICD technology is needed, which will hope-
fully address these issues.
Conclusions
Idiopathic VF patients have a high recurrence rate of ven-
tricular arrhythmias, even after the systematic exclusion of
patients with the Brugada syndrome or other known elec-
trical diseases from the analysis. ICD prevents sudden car-
diac death in this population, but treat only the final
manifestation of an unknown disease. Inappropriate
shocks remain a major concern in this young population.
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